Review article

Vascular biology of ageing—Implications in hypertension

Adam Harvey, Augusto C. Montezano, Rhian M. Touyz *

Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK

A B S T R A C T

Ageing is associated with functional, structural and mechanical changes in arteries that closely resemble the vascular alterations in hypertension. Characteristic features of large and small arteries that occur with ageing and during the development of hypertension include endothelial dysfunction, vascular remodelling, inflammation, calcification and increased stiffness. Arterial changes in young hypertensive patients mimic those in old normotensive individuals. Hypertension accelerates and augments age-related vascular remodelling and dysfunction, and age may impact on the severity of vascular damage in hypertension, indicating close interactions between biological ageing and blood pressure elevation. Molecular and cellular mechanisms underlying vascular alterations in ageing and hypertension are common and include aberrant signal transduction, oxidative stress and activation of pro-inflammatory and pro-fibrotic transcription factors. Strategies to suppress age-associated vascular changes could ameliorate vascular damage associated with hypertension. An overview on the vascular biology of ageing and hypertension is presented and novel molecular mechanisms contributing to these processes are discussed. The complex interaction between biological ageing and blood pressure elevation on the vasculature is highlighted. This article is part of a Special Issue entitled: CV Ageing.

© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).

Contents

1. Introduction .......................................................... 113
2. Structural and mechanical changes in the ageing vasculature ................................................ 113
3. Vascular calcification ............................................... 114
4. Ageing associated vascular inflammation .............................................................................. 114
5. Vascular contractility and ageing ......................................................................................... 114
6. Endothelial function and ageing .......................................................................................... 114
7. Vascular signalling in ageing ............................................................................................... 114

7.1. Sirtuins .................................................................. 114
7.2. PGC-1α .................................................................. 115
7.3. FoxO transcription factors .................................................. 115
7.4. p66shc .................................................................. 115
7.5. Cell cycle regulators, senescence and autophagy ......................................................... 116
7.6. Mitogen-activated protein kinases (MAPK) .............................................................. 116
7.7. Oxidative stress in vascular ageing ................................................................................. 116
7.8. Endoplasmic reticulum stress in vascular ageing ......................................................... 116
7.9. Vascular changes in hypertension recapitulate those in ageing .................................. 117
7.10. Effects of pro-hypertensive stimuli on vascular ageing: the renin–angiotensin–aldosterone system (RAAS) ......................................................... 117
7.11. Effects of novel anti-hypertensive factors on vascular ageing .................................. 118
7.12. Vascular damage in hypertension may be independent of ageing ......................... 118
7.13. Lessons learned from children with hypertension ...................................................... 118
8. Summary and conclusions ................................................................................................. 119

* Corresponding author at: Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, 126 University Place, Glasgow, G12 8TA, UK. Tel.: + 44 141 330 7775/7774; fax: + 44 141 330 3360.
E-mail address: Rhian.Touyz@glasgow.ac.uk (R.M. Touyz).

http://dx.doi.org/10.1016/j.yjmcc.2015.04.011
0022-2828/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Clinical studies show a significant relationship between ageing and increased blood pressure, with advancing age being a major non-modifiable risk factor in the development of hypertension [1]. This is due, in part, to changes that occur in the vasculature, including endothelial dysfunction, vascular remodelling, increased vascular stiffness and inflammation. These functional and structural changes define the ‘vascular phenotype’ of hypertension, features that are also found during ageing [2] (Fig. 1). At the cellular level, there is endothelial cell damage, increased vascular smooth muscle cell growth, cell migration, inflammation, contraction, extracellular matrix deposition, fibrosis, and calcification [3].

Young patients with elevated blood pressure exhibit arterial changes similar to those in older individuals with normal blood pressure, and accordingly the concept of ‘premature’ or ‘early’ vascular ageing in hypertension has been proposed [4]. Hypertension accelerates age-related vascular changes, processes that are attenuated when blood pressure is normalised. The direct relationship between ageing and vascular health is evident in progeria syndrome, where patients exhibit accelerated ageing, endothelial dysfunction, accelerated atherosclerosis and die prematurely from complications of cardiovascular disease, such as stroke and myocardial infarction [5]. Considering the fact that the population is ageing and that the major chronic disease of ageing is hypertension and associated cardiovascular complications, the potential health and economic burden in our modern society is enormous. Accordingly it is important to understand how vascular function changes with ageing and how this impacts on hypertension, so that targeted strategies could be developed to prevent and repair damaged ‘aged’ arteries and thereby reduce the risk of hypertension and target organ damage. In the present review, we discuss the vascular changes that occur with ageing and during the development of hypertension and focus on some molecular mechanisms that underlie these vascular changes.

2. Structural and mechanical changes in the ageing vasculature

Physiological changes to the vascular wall are dynamic and occur throughout life [6,7]. Endothelial cell turnover occurs over years, whereas that of vascular smooth muscle cells seems to occur over a shorter time period. Many structural and mechanical alterations have been observed in the aged vasculature including increased intimal-to-media (IM) thickness, evidenced by the finding that the IM thickness of the carotid artery increases two- to three-fold between 20 and 90 years of age [8,9]. Subclinical IM thickening is strongly associated with ageing and is also a predictor of future cardiovascular events [8,9]. Both aortic length and circumference gradually increase with advancing age [10–12]. Associated with these structural alterations are mechanical changes, characterised by a reduction in compliance, reduced elasticity/distensibility and increased stiffness [8,9]. Stiffening of the large conduit arteries due to fracture of elastin fibres within the tunica media and collagenous remodelling, results in increased aortic pulse pressure and pulse wave velocity (PWV). Increased PWV, a non-invasive measure of vascular stiffness, increases in both sexes with ageing and is determined by the mean arterial pressure and the intrinsic stress/strain relationship (stiffness) of the arterial wall. As arterial wall stiffness increases, central systolic pressure increases and diastolic pressure decreases, leading to increased pulse pressure, an independent risk factor for future cardiovascular events [13]. Processes underlying these structural and mechanical changes involve growth and migration of vascular smooth muscle cells...
within the media, vascular calcification and changes in the ratio of collagen and elastin in the vascular wall. Physiologically, the ratio of collagen and elastin remains constant due to their gradual production and degradation. In aged rodents the absolute elastin content of the aorta was shown not to differ to young counterparts. However, increased collagen content in 30-month-old animals compared to 6-month-old animals meant that the relative elastin content was decreased [14]. Collagen and elastin are regulated by catabolic matrix metalloproteinases (MMPs). Throughout ageing the balance between MMPs and their inhibitors (TIMPs) changes. For example, increased MMP-2 expression and activity in the vessels of old rats and non-human primates is increased compared to young counterparts [15,16].

3. Vascular calcification

Vascular calcification is a tightly controlled process similar to bone formation, where mineralization of the internal elastic lamina and elastic fibres in the media results in vascular stiffening. Calcification of the vascular media is a hallmark of vascular ageing [17]. Upregulation of transcription factors such as cfbf1 (core-binding factor 1α)/Runx2, MSX-2 and bone morphogenetic protein 2 (BMP-2), are involved in normal bone development and vascular calcification by regulating the expression of osteogenic proteins, including osteocalcin, osteonectin, alkaline phosphatase, collagen-1, and bone sialoprotein [18,19]. Another mechanism contributing to vascular mineralization is loss of calcification inhibitors, such as fetuin-A, matrix Gla protein, pyrophosphate, and osteopontin [19–21]. Molecular processes underlying this remain to be fully defined but increased expression of BMP2 and the osteoblast transcription factor Runx2/Chfα1 [22], and modulation of Ca2+ and Mg2+ transport through cation channels, such as TRPM7 may represent important mediators in this process [23,24]. A correlation between age and vascular calcification has been described from 5% in individuals younger than 50 years to >12% in individuals older than 80 years [25]. Ageing-associated vascular calcification has been reported in the aorta of rodents where the associated mechanisms include dysregulation of Matrix Gla protein [26]. Further possible mechanisms contributing to increased calcification with ageing includes dysregulation of vascular pyrophosphate [27,28]. Human studies have shown a weak inverse correlation between age and plasma pyrophosphate [29,30].

4. Ageing associated vascular inflammation

With ageing there is a shift towards a proinflammatory vascular phenotype with upregulation of inflammatory cytokines, chemokines and adhesion molecules in the vascular wall [8,9,31–38]. Pro-inflammatory transcription factors and proteins that have been identified in the ageing vascular media include MCP-1, TGF-β1, MPP-2, AP-1 and NF-kB [8,9,39]. Expression and activation of these molecules increases with ageing, processes that are usually associated with increased generation of reactive oxygen species (ROS). In aged arteries, there is downregulation of the transcription factor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), which stimulates expression of antioxidant enzymes, thereby leading to decreased anti-oxidant potential and increased ROS bioavailability with consequent oxidative stress [40]. Oxidative stress is a potent inducer of redox-sensitive pro-inflammatory signalling pathways, further contributing to inflammation and vascular damage with ageing [36–40].

5. Vascular contractility and ageing

Functionally, vascular contraction is altered during ageing and is determined in large part by changes in vascular smooth muscle cell cytoskeletal organisation and impaired contractile signalling. Mesenteric arteries from aged rats demonstrate hypercontractility in response to phenylephrine compared to young controls [40] an effect which is mirrored in the aorta [41]. These findings are paralleled in studies utilising the senescence-accelerated mouse (SAM-P8), which demonstrate increased vascular contractility in response to phenylephrine [42]. Conversely, studies performed on carotid vessels from aged guinea pigs displayed reduced contractile response to both phenylephrine and endothelin-1 (ET-1) compared to younger controls [43]. Thus it appears that differential responses during ageing may differ between species.

At the cellular level, with ageing, vascular smooth muscle cells, which are normally contractile, undergo phenotypic changes to become stiff and pro-migratory. Subsets of apoptotic, senescent and proliferative cells as well as hyper-contractile cells may co-exist in the vascular media. A major trigger for these functional changes is an increase in intracellular free Ca2+ concentration ([Ca2+]i), which occurs following activation of phospholipase C (PLC) leading to the generation of second messengers inositol trisphosphate (IP3) and diacylglycerol (DAG) [39,44]. Ca2+ binds to calmodulin facilitating an interaction with myosin light chain kinase (MLCK) leading to its activation. Activated MLCK triggers phosphorylation of the regulatory light chains of myosin (MLC20) promoting cycling of myosin cross-bridges with actin and consequent contraction. Dephosphorylation of MLC20 by myosin light chain phosphatase (MLCP) results in VSNC relaxation. As such, the relative activities of MLCK and MLCP determine vascular smooth muscle tone by influencing the degree of MLC20 phosphorylation. Arteries from aged animals display altered responses to various contractile agents including norepinephrine, serotonin and KCl [44,45]. Mechanisms for this are incompletely understood, but the percentage of phosphorylated MLC20 induced by vasoactive agonists is different in young versus aged rats and may play a role in altered age-related contractile responses [45].

6. Endothelial function and ageing

The vascular endothelium is a monolayer of cells that lines blood vessels and plays a key role in arterial function through synthesis and release of biologically active molecules that can influence endothelial function in an autocrine or paracrine fashion. The healthy endothelium is characterised by a vasodilatory, anti-inflammatory and anti-thrombotic phenotype. Endothelial dysfunction is characterised by reduced vasodilatory responses to flow or agonists and is pro-inflammatory. Independent of the occurrence of other pathologies, ageing results in altered endothelium-dependent relaxation of both the aorta and resistance arteries in rodents [46,47]. These findings have been corroborated in human studies that suggest that endothelial function is gradually compromised with ageing [48,49]. A primary mechanism responsible for the deterioration of endothelial function with ageing is thought to be reduced bioavailability of the endothelium derived relaxing factor, nitric oxide (NO), due to its interaction with ROS to form peroxynitrite. Peroxynitrite oxidises BH4, an essential cofactor for NO synthesis by endothelial nitric oxide synthase (eNOS), to its inactive form resulting in reduced NO production. Furthermore, reduced BH4 can result in eNOS uncoupling whereby superoxide is produced in preference to NO. Reductions in BH4 levels have been reported in aged rodents [50].

7. Vascular signalling in ageing

Molecular mechanisms and cell signalling events underlying the structural and functional alterations observed during ageing are similar to those that occur in hypertension (Fig. 2). Many age/longevity-related molecules and signalling cascades have been described, of which a few of the novel systems are highlighted below.

7.1. Sirtuins

Sirtuins (SIRTs) are a family of NAD-dependent protein deacetylases and ribosyl transferases consisting of 7 members which are localised in the cytoplasm (SIRT1 and SIRT2), nucleus (SIRT1, SIRT2, SIRT6 and SIRT7) or mitochondria (SIRT3, SIRT4 and SIRT5). SIRTs have been
implicated in various cellular processes associated with ageing, including apoptosis, inflammation and mitochondrial biogenesis. SIRTs are able to modulate the ageing process in a number of species [51–53]. This is highlighted by the following: 1) SIRT1 protects against phosphate-induced arterial calcification, possibly due to the inhibition of osteoblastic transdifferentiation [54]; 2) mitochondrial localised SIRT3 regulates many proteins that are important in the regulation of mitochondrial function including pyruvate dehydrogenase, SOD2 and cyclophilin D; 3) SIRT3−/− mice exhibit accelerated cardiovascular ageing [55] and 4) SIRT3 has vasoprotective effects through interaction with FOXO3, which enhances mitochondrial antioxidant defence systems [56].

7.2. PGC-1α

Another emerging candidate implicated in age-related signalling in the vasculature, is peroxisome proliferator-activated receptor gamma coactivator-1α (PGC-1α), which plays an important role in regulating mitochondrial biogenesis and turnover [57]. Because mitochondria require continuous recycling and regeneration throughout the lifespan and are subject to continuous damage over time, regulation of mitochondrial biogenesis and turnover is critical for maintained energy production and prevention of oxidative damage, and the promotion of healthy ageing. Impaired mitochondrial biogenesis is an important inducer of age-related changes in the endothelium and vascular smooth muscle [58–60]. The aged vasculature displays reduced levels of PGC-1α with consequent mitochondrial dysregulation of the electron transport chain and other mitochondrial proteins leading to oxidative stress and vascular injury [60]. Decreased AMPK activity may contribute to reduced PGC-1α activation and impaired mitochondrial function associated with ageing [61].

7.3. FoxO transcription factors

The FoxO family of Forkhead transcription factors are involved in tumour suppression, energy metabolism, and longevity. Mammals express four FoxO isoforms, FoxO1, FoxO3, FoxO4 and FoxO6. FoxO1, FoxO3 and FoxO4 are phosphorylated in an Akt-dependent manner that promotes FoxO export from the nucleus to the cytoplasm, thereby repressing FoxO transcriptional function. FoxO targets include genes that have pivotal roles in cell cycle progression (p21, p27) and ROS detoxification (MnSOD) and thus may be important in regulation of the ageing phenotype in the vasculature [62,63]. FoxO3 is a direct target of SIRT3 deacetylation protecting mitochondria against age-related oxidative stress and promoting upregulation of genes that are essential for mitochondrial homeostasis [64]. Several reports have suggested that FoxO3 may be a determinant of ageing, due to the fact that single-nucleotide polymorphisms in the FoxO3 gene are associated with longevity in humans [65,66]. FoxO3 knockout mice however do not exhibit reduced lifespan [67], and as such, the exact role of FoxO3 in longevity and ageing still remains unclear.

7.4. p66Shc

Mitochondrial dysfunction and increased mitochondrial-derived ROS have been implicated in vascular changes in ageing [68]. An important mediator of mitochondrial ROS production and thus regulator of the intracellular pathways that govern oxidative stress, apoptosis, and...
cell growth/survival is the adapter protein p66Shc. p66Shc is phosphorylated at serine 36 by PKCζ and VEGF, resulting in recognition by the prolyl isomerase Pin1, allowing translocation and entrance into mitochondria where it interacts with cytochrome C resulting in production of H2O2. Levels of p66Shc in heart, kidney and vascular smooth muscle increase with ageing [69]. Mice lacking p66Shc gene display a 30% increase in lifespan compared to wild-type controls due to prevention of oxidative stress and improved endothelial function [70,71].

7.5. Cell cycle regulators, senescence and autophagy

In culture, vascular cells respond to prolonged series of replication and stresses by eventually entering an irreversible growth arrest or senescent state [72]. After the Hayflick limit, cells enter an irreversible cell cycle arrest in the G1 phase of the cell cycle and no longer respond to growth stimuli. This phenomenon is called replicative senescence and occurs in vascular ageing [73]. Senescent cells have a distinct phenotype—they are large and flattened, express specific markers (β-galactosidase), overexpress cell cycle molecular markers (p16 and p21), form heterochromatic foci (γH2AX) and accumulate lipofuscin, a non-degradable fluorescent compound [74]. Whilst the molecular mechanisms underlying cellular senescence have been the focus of numerous studies, the impact of senescence in vivo has yet to be fully established, especially since some studies show increased rates of vascular cell proliferation in ageing and longevity [75,76].

Considering the remarkable plasticity of vascular smooth muscle cells, there is a requirement for tight control of transcriptional, metabolic and ultrastructural processes, events that are coordinated through autophagy. Autophagy is the basic cellular mechanism that involves cell degradation of unnecessary or dysfunctional molecules through lysosomes [77]. In the vasculature, changes in autophagy have been observed in experimental ageing [78].

7.6. Mitogen-activated protein kinases (MAPK)

Protein kinases are major regulators of signal transduction that catalyse the phosphorylation of other proteins, thus regulating their activity. Primary targets of protein kinases include transcription factors which modulate intracellular signalling via specific alteration of downstream gene expression/activity [79]. A key group of protein kinases in the vasculature are the serine/threonine sub-family, which act by promoting phosphorylation of the OH group of serine or threonine residues on target proteins [80]. Mitogen activated protein kinases (MAPks) represent a large family of proteins important in signal transduction within the cardiovascular system, where they are involved in regulation of a number of biological processes, such as cell migration, survival, apoptosis, proliferation, contraction and differentiation. MAPK signalling is promoted by many stimuli including GPCR activation, receptor tyrosine kinases, oxidative stress and growth factors, and comprises a number of sequentially acting kinases which ultimately result in phosphorylation and activation of terminal effector kinases, thereby transducing specific cellular actions [80,81]. Several MAPK family subgroups have been identified, of which the major mammalian types appear to be ERK1/2, c-Jun NH2-terminal kinases (JNK1, 2 and 3) and p38MAPK (∝, β, γ, and δ), which play key roles during cardiovascular development and vascular function [82,83]. Several studies have demonstrated an age-dependent increase in MAPK activation in vascular tissue [84,85].

7.7. Oxidative stress in vascular ageing

Common to many of the molecular and cellular processes described above that underlie changes in the vasculature with ageing is oxidative stress [86]. The concept that ROS are linked to ageing was suggested in 1956 by Harman when he proposed the Free Radical Theory of Ageing, stating that the accumulation of free radicals during ageing causes the damage of biomolecules by these ROS and the development of pathological disorders promoting cell senescence and organism ageing [87,88]. Such processes are evident in vessels associated with ageing and with hypertension [87,88]. Excessive production of ROS and reactive nitrogen species (RNS) leads to oxidative modification of proteins, DNA and lipids, which accumulate in cells leading to impaired cellular and vascular function. In addition increased vascular ROS levels, together with decreased eNOS-generated NO, compromise the vasodilatory actions of NO and promote the formation of injurious peroxynitrite, processes observed in aorta of aged rodents [89]. Oxidative stress is critically involved in many of the molecular events of vascular ageing, including: (1) increased pro-inflammatory responses in vascular cells, (2) vascular dysfunction through oxidative modification of structural and functional proteins regulating vascular contraction/relaxation, fibrosis and calcification, (3) altered calcium homeostasis in vascular cells, (4) activation of redox-sensitive pro-inflammatory and profibrotic transcription factors, and (4) activation of molecular mechanisms leading to senescence and autophagy in endothelial and vascular smooth muscle cells [Fig. 3]. The fact that SOD mimetics, such as tempol, normalise endothelial dysfunction in old rodents supports a role for increased superoxide anion levels in age-related endothelial impairment [90].

Changes in cellular anti-oxidant systems are also important. The expression and activity of antioxidant enzymes, including SOD, decline as tissues age. Decreased anti-oxidant capacity is further promoted by downregulation of Nrf2, the master transcription factor regulating anti-oxidant genes [91]. These processes are accompanied by chronic low-grade inflammation mediated by redox-sensitiveNhB, which is upregulated in aged vessels [92].

Multiple oxidases generate ROS in the vascular wall and endothelium, including NADPH oxidases (Nox), xanthine oxidase, uncoupled NO and mitochondrial oxidases. Of these, mitochondria seem to play a major role in processes related to ageing. Noxs, of which there are 7 isoforms (Nox1-5, Duox1, Duox2), have also been shown to contribute to oxidative stress in vascular ageing [93–95]. In particular, in aged spontaneously hypertensive rat aortas, expression of Nox1 and Nox2, but not of Nox4, was increased. This Nox upregulation was associated with endothelial dysfunction, which was reversed by VAS2870, a Nox inhibitor [96]. Nox appear to be more important in pathological vascular remodelling associated with hypertension and cardiovascular diseases [97–99]. Vascular xanthine oxidase and cytochrome P450 epoxygenases seem to be less important, since expression and activity of these systems is not altered with ageing in humans [100].

With biological ageing, mitochondria become dysfunctional leading to reduced energy production and increased ROS formation. Mechanisms related to mitochondrial dysfunction during ageing include decreased ATP synthesis, increased apoptosis and mutations of mitochondrial DNA by oxidation [101]. During ageing, the electron flow in mitochondria decreases, altering the oxygen consumption and inducing ROS generation [101]. The pro-oxidative environment increases mitochondrial DNA damage, leading to further dysfunction of the respiratory chain and more ROS production. Consequently, the rate of apoptosis increases, releasing an excessive amount of ROS into the cytosol, further contributing to oxidative stress and vascular cell damage.

7.8. Endoplasmic reticulum stress in vascular ageing

Prolonged perturbation of the endoplasmic reticulum (ER) leads to ER stress and unfolded protein response (UPR) and contributes to pathogenic processes associated with vascular damage and endothelial dysfunction [102]. The ER is an important site where proteins are folded and post-translation modifications occur. It is also a site for Ca2+ storage and cholesterol/lipid biosynthesis. Due to the large amount of unfolded protein in the ER, a control system that avoids protein aggregation and accumulation of unfolded proteins is necessary. In experimental models of ageing, the expression and activity of ER chaperones or folding enzymes decay, whilst oxidative damage, such as carbonylation, is
exacerbated, leading to accumulation of misfolded/unfolded proteins and ER stress. This activates signalling mechanisms that are part of the UPR. Induction of ER stress leads to endothelial cell apoptosis, but not senescence, implicated in endothelial dysfunction in ageing [103,104]. Inhibition of ER stress has been suggested as a novel therapeutic strategy to ameliorate vascular dysfunction during ageing [105]. However such approaches still require further investigation.

7.9. Vascular changes in hypertension recapitulate those in ageing

Many of the signalling pathways associated with vascular changes during ageing are also activated in hypertension leading to endothelial dysfunction, vascular inflammation, remodelling and increased arterial stiffness. With normal physiological ageing the process is gradual and regulated but in itself represents a strong and independent risk factor for hypertension and future cardiovascular events [106]. In susceptible individuals, due to genetic, environmental or in-utero factors (fetal programming), processes underlying vascular changes are accelerated leading to ‘early vascular ageing’, which predisposes to cardiovascular disease. Numerous risk factors amplify the process of arterial ageing, including atherosclerosis, smoking, increased sodium intake and hypertension, due, in part, to increased oxidative stress, activation of pro-inflammatory and pro-fibrotic signalling pathways and upregulation of the renin–angiotensin–aldosterone system. As with ageing, experimental and human hypertension show a reduction in endothelium-dependent vasodilation, decreased NO bioavailability, NO synthase uncoupling, increased oxidative stress, telomere shortening and associated endothelial dysfunction. In arteries from aged humans, non-human primates and rodents, expression of the AT1R is increased and sensitivity of the mineralocorticoid receptor to aldosterone is enhanced, phenomena that are also observed in hypertension [107–109]. Ang II promotes vascular calcification, inflammation, cell proliferation and fibrosis and mimics age-associated vascular remodelling in young rodents [110–112]. In large arteries these molecular and cellular processes manifest as increased arterial stiffness, which is a major contributor to elevated central blood pressure leading to isolated systolic hypertension, common in the elderly. Exactly what triggers these cellular and vascular events remains unclear, and it is difficult to dissect out the ‘ageing effect’ from the ‘blood pressure effect’. This ‘conundrum of arterial stiffness, elevated blood pressure and ageing’ has recently been reviewed by AlGhatrif and Lakatta [113], who concluded that vascular properties depend on the net effect of multiple factors that are interdependent and which change with ageing over a lifetime.

7.10. Effects of pro-hypertensive stimuli on vascular ageing: the renin–angiotensin–aldosterone system (RAAS)

The RAAS plays an important role in functional, structural and mechanical changes of the vasculature that occur with ageing and hypertension [114]. This occurs through increased signalling via the AT1 receptor. Expression of various components of the RAS, including angiotensinogen, chymase, angiotensin converting enzyme (ACE) and the AT1 receptor is increased in arteries of aged rodents and humans [8,9]. To further support a role for the RAAS in the ageing process and during hypertension are studies showing that ACE inhibitors and AT1 receptor blockers decrease ageing-associated vascular damage. Mice
treated with enalapril or losartan demonstrated vasoprotection and an increase in life span [115,116]. Processes associated with these effects involve upregulation of NOS activity and increased NO production. An increase in antioxidant defences, such as SOD and glutathione, is another mechanism involved in the anti-ageing effects of the inhibition of the RAAS system, leading to an increase in NO bioavailability [117]. Moreover, lifelong treatment of young stroke-prone spontaneously hypertensive rats, with AT1 receptor blockers doubles the lifespan by improving endothelial function and alleviating complications of hypertension [118]. To further support a role for Ang II/AT1 receptor in oxidative stress, vascular injury and ageing, studies in mice with targeted disruption of the Agtr1a gene, which encodes the AT1A receptor, resulted in prolonged life span [119]. Agtr1a−/− mice developed less cardiac and vascular injury and oxidative damage was reduced compared with wild-type counterparts. The longevity phenotype was associated with an increased number of mitochondria and upregulation of pro-survival genes.

Clinical and experimental studies demonstrate that many prohypertensive systems influence processes of vascular ageing, including aldosterone, ET-1 and growth factors [120–124]. Arteries from aged rodents demonstrate upregulation of these systems, leading to stimulation of signalling pathways, oxidative stress, and activation of pro-inflammatory transcription factors, which promote a shift of endothelial and vascular smooth muscle cells to an ageing phenotype. On the other hand, infusion of Ang II, aldosterone or ET-1 in young animals, recapitulates arterial changes observed in aged animals.

7.11. Effects of novel anti-hypertensive factors on vascular ageing

NO is a potent vasodilator produced by endothelial cells that mediates vascular relaxation and thus plays a critical role in the regulation of blood flow. Abnormalities in endothelial production of NO occur in hypertension and are due, in large part, to decreased eNOS activity [125]. NO donors such as glyceryl trinitrate (GTN) have been shown to possess anti-hypertensive properties [126] and evidence is emerging that NO and NO donors could confer beneficial effects on the phenotypic alterations that occur in the vasculature with ageing. For example, NO prevents differentiation of VSMCs into osteoblastic cells by inhibiting TGF-β [127]. The NO donor S-nitroso-penicillamine significantly reduces endothelial cell senescence and age-dependent inhibition of telomerase activity [128,129].

The gaseous messenger hydrogen sulphide (H2S) produced by cystathionine γ-lyase (CSE) or cystathionine β-synthase (CBS) has recently emerged as a novel antihypertensive factor based on the observations that exogenous H2S is vasoprotective in pulmonary hypertension [130] and that it reduces systemic blood pressure by improving endothelial function [131]. CSE-deficient mice, have increased blood pressure and impaired endothelial function [132]. Mouse embryonic fibroblasts from CSE knockout mice display accelerated cellular senescence and increased expression of p53 and p21, processes which were prevented by NaHS treatment. NaHS also enhanced Nrf2 nuclear translocation, and stimulated mRNA expression of Nrf2-targeted down-stream anti-oxidant genes in this system, highlighting an important interplay between cellular ageing, senescence and oxidative stress [133]. Attenuation of endothelial cell senescence by H2S occurs through modulation of SIRT1 activity [134].

Plasma levels of H2S in humans decline with age [135] and several studies have shown that H2S protects against free-radical-induced damage and exerts beneficial effects on age-associated diseases [136]. Several lines of evidence indicate that these beneficial effects may extend to vascular ageing, characterised by positive effects on many of the phenotypic vascular alterations that occur with advancing age. For example, the production of H2S is decreased in a rodent model of vascular calcification with the addition of H2S ameliorating this phenotype [137]. Further, in vascular smooth muscle cells, H2S was found to inhibit calcium deposition in the extracellular matrix and suppress induction of osteoblastic transformation genes [138].

In endothelial cells stimulated with TNF-α, NaHS (HZS donor) suppressed pro-inflammatory responses by reducing the TNF-induced increase in expression of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), P-selectin and E-selectin. Furthermore, TNF-α-induced NF-κB was decreased in the presence of NaHS [139]. H2S donors (NaH and Na2S) can inhibit leukocyte adherence in mesenteric venules whilst inhibition of endogenous H2S synthesis promotes leukocyte adhesion and vascular inflammation [140].

7.12. Vascular damage in hypertension may be independent of ageing

Although there are many signalling pathways and functional and structural characteristics that are common in vessels during ageing and hypertension, these processes are dynamic and change throughout life and as such may not necessarily be superimposable. For example, with advancing age arterial stiffness and blood pressure start to diverge rather than parallel [141]. Also, circulating markers of inflammation including sVCAM-1, IL-6 and MCP-1 increase with age but do not necessarily correlate with elevations in blood pressure [142]. Furthermore, with ageing, aortic calcification is independently predictive of subsequent vascular morbidity and mortality beyond established risk factors with no evident correlation between calcification and systolic BP [143]. There is also some evidence to show that structural alterations in the vascular wall occur before the development of hypertension. For example rates of pulse wave velocity (PWV) increase are accelerated with both advancing age and elevated blood pressure. However, the effect of blood pressure on PWV increase occurs primarily during the prehypertensive phase and suggests that these vascular alterations precede the phase of established hypertension [8,144].

7.13. Lessons learned from children with hypertension

Vascular changes that occur with ageing may be independent of biological ageing in hypertension. This is highlighted in studies that have examined vascular function and arterial structure in children with hypertension. Endothelial dysfunction, arterial stiffening and structural alterations of the arterial wall may precede evidence of high blood pressure, as quantified by systolic and diastolic blood pressure, and may be independent of the ageing process [145]. This is evidenced by the findings that vascular injury is already present in children with mild hypertension, processes that are exaggerated as hypertension becomes more severe [146,147]. Functional alterations, including reduced endothelium-dependent vasorelaxation and decreased elasticity, seem to precede vascular structural changes. In obese pre-pubertal children, impaired brachial endothelial and vascular smooth muscle function is present without concomitant increase in carotid intima-to-media thickness. Functionally these changes lead to decreased vascular distensibility and increased rigidity or stiffness. Arterial stiffness, as assessed by measurement of PWV, is increased in children with type 1 diabetes and in children with hypertension. Increased arterial stiffness in childhood hypertension is an important risk factor for severe hypertension and cardiovascular complications later in life. Results from the Amsterdam Growth and Health Longitudinal Study indicate that individuals with stiffer carotid arteries at age 36 years of age were characterised during adolescence by increased blood pressure and increased PWV [148]. Factors that have been implicated in vascular dysfunction in childhood hypertension include activation of the sympathetic nervous system, adipokines, upregulation of the RAAS and increased oxidative stress, processes that also underlie physiological vascular ageing and EVA in adult hypertension [149–152].

Taken together, emerging experimental and clinical evidence indicates that although the molecular and cellular processes that characterise the vascular phenotype in hypertension resemble those that occur with normal healthy ageing, age per se may not be a critical
factor. However, ageing may be a compounding factor that amplifies vascular injury that occurs with blood pressure elevation. In the presence of other co-morbidities, such as diabetes, dyslipidemia, smoking and obesity, these processes may be further exaggerated.

8. Summary and conclusions

Ageing is associated with a progressive deterioration in endothelial function, vascular remodelling, inflammation and increased arterial stiffness. Processes underlying these processes include activation of pro-inflammatory transcription factors, oxidative stress, cell senescence and apoptosis, aberrant signalling cascades and a shift from a vasoconstrictor to a proliferative vascular cell phenotype. Many of these phenomena are also relevant in the pathophysiology of hypertension, which is characterised by a vascular phenotype of impaired endothelium-dependent vasorelaxation, arterial remodelling, increased stiffness and vascular inflammation. Through such vascular changes, ageing and hypertension are closely interlinked: ageing promotes hypertension and pro-hypertensive factors promote vascular ageing. Whilst many of the molecular processes and signalling pathways contributing to vascular dysfunction are common in ageing and in hypertension, biological age per se, may not be a fundamental factor, since vascular damage is already present in children and young adults with hypertension. A better understanding of the vascular biology of ageing will facilitate development of strategies to promote healthy vessels and suppress age-associated changes, especially in pathological conditions. Such approaches could prevent or ameliorate vascular damage in hypertension and hence reduce cardiovascular diseases, commonly linked to ageing.

Disclosures

There are no disclosures to declare.

Acknowledgements

Work from the author’s laboratory was supported by grants 44018 and 57886, from the Canadian Institutes of Health Research (CIHR) and grants from the British Heart Foundation (BHF) RG/13/7/30099. RMT is supported through a BHF Chair CH/12/4/29762. ACM is supported through a Leadership Fellowship from the University of Glasgow.

References

[1] Wang M, Monticone RE, Lakatta EG. Arterial aging: a journey into subclinical arterial disease. Curr Opin Nephrol Hypertens 2010;19(2):201–7.
[2] Basra C. Updating the mitochondrial free radical theory of aging: an integrated view, key aspects, and confounding concepts. Antioxid Redox Signal 2013; 19(12):1420–45.
[3] Bachschmid MM, Schildknecht S, Matsui R, Zee R, Haeseler D, Cohen RA, et al. Vascular aging: chronic oxidative stress and impairment of redox signalling—consequences for vascular homeostasis and disease. Ann Med 2013;45(1):17–30.
[4] Ross R, Stabouli S, Karfalias I, Nilsson P. Early vascular aging and the role of central blood pressure. J Hypertens 2011;29(10):1847–53.
[5] Gerstenblith G, Frederiksen J, Yin FC, Fortuin NJ, Lakatta EG, Weisfeldt ML. Echocardiographic assessment of a normal adult aging population. Circulation 1977;56(2):273–8.
[6] Virmanni R, Avolio AF, Mengher WJ, Robinowitz M, Herderick EE, Corwin HJ, et al. Effect of age on aortic morphology in populations with high and low prevalence of hypertension and atherosclerosis. Comparison between occidental and Chinese communities. Am J Pathol 1991;138(5):1119–29.
[7] Sugawara J, Hayashi K, Yokoi T, Tanaka H. Age-associated elongation of the ascending aorta in adults. JACC Cardiovasc Imaging 2008;1(6):739–48.
[8] Nilsson PM, Khalil P, Franklin SS. Blood pressure and pulse wave velocity as metrics for evaluating pathologic ageing of the cardiovascular system. Blood Press 2014; 23(1):17–30.
[9] Michel J, Heudes D, Michel O, Poitevin P, Philippe M, Scalbert E, et al. Effect of chronic ANG I-converting enzyme inhibition on ageing processes. II. Large arteries. Am J Physiol 1994;267:C124–R124.
[10] Wang M, Takagi G, Asai K, Resuello RG, Natividad FF, Vatner DE, et al. Aging increases aortic MMP-2 activity and angiogenesis II in nonhuman primates. Hypertension 2003;41(6):1308–18.
[11] Li Z, Frohlich J, Galis ZS, Lakatta EG. Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. Hypertension 1999; 33(1):116–23.
[12] Jiang L, Zhang J, Monticone RE, Telljohann R, Wu J, Wang M, et al. Calpain-1 regulation of matrix metalloproteinase-2 activity in vascular smooth muscle cells facilitates age-associated aortic wall fibrosis and fibrosis. Hypertension 2012; 60(5):1192–9.
[13] Shanahan CM. Mechanisms of vascular calcification in CKD—evidence for prema-

ture ageing? Nat Rev Nephrol 2013;9(11):661–70.
[14] Alam MU, Kirton JP, Wilkinson FL, Towers E, Sinha S, Rouhi M, et al. Calcification is associated with loss of functional calcium-sensing receptor in vascular smooth muscle cells. Cardiovasc Res 2009;81(1):260–8.
[15] Rosito GA, Massaro JM, Hoffmann U, Ruberg FL, Mahabadi AA, Vasan RS, et al. Peri-
cardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008;117(5):605–13.
[16] McCarty MF, DiNicolantonio JJ. The molecular biology and pathophysiology of vascular calcification. Postgrad Med 2014;124(2):54–64.
[17] Trekal M, Ginnan R, Singer HA, Jourd’heuil D. Interplay between calcium and reac-
tive oxygen/nitrogen species: an essential paradigm for vascular smooth muscle signaling. Antioxid Redox Signal 2010;12(5):657–74.
[18] Louvet L, Büchel J, Steppan S, Passlick-Deetjen J, Massy ZA. Magnesium prevents phosphate-induced calcification in human aortic vascular smooth muscle cells. Nephrol Dial Transplant 2013;28(4):869–78.
[19] Montezano AC, Zimmerman D, Yusuf H, Burger D, Chignalia AZ, Wadhera V, et al. Vascular smooth muscle cell differentiation to an osteogenic phenotype involves TRPM7 modulation by magnesium. Hypertension 2010 Sep;56(5):453–62.
[20] McClelland RL, Chung H, Detrano R, Post W, Kronmal RA. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA). Circulation 2006;113(1):30–7.
[21] Swart A, Sane D, Hutson S, Wallin R. Matrix GlA protein (MGP) and bone morpho-

geneic protein-2 in aortic calcified lesions of aging rats. J Thromb Haemost 2003; 1(1):178–85.
[22] Rutsch F, Nitschke Y, Terkeelba R. Genetics in arterial calcification: pieces of a puzzle and cogs in a wheel. Circ Res 2011;109(5):578–92.
[23] Leopold JA. Vascular calcification: an age-old problem of old age. Circulation 2013; 127(4):2380–2.
[24] Lomashvili RA, Khawwash W, O’Neill WC. Reduced plasma pyrophosphate levels in hemodialysis patients. J Am Soc Nephrol 2005;16(5):2405–90.
[25] O’Neill WC, Sigrist MK, McIntyre CW. Plasma pyrophosphate and vascular calcification in chronic kidney disease. Nephrol Dial Transplant 2010;25(11):187–91.
[26] Wang M, Monticone RE, Lakatta EG. Proinflammation of aging arterial curves: a mini-review. Gerontology 2014;60(6):519–28.
[27] Cisizar A, Ungvari Z, Edwards JG, Kaminski P, Wolin MS, Koller A, et al. Aging induced phenotypic changes and oxidative stress impair coronary arterial function. Circ Res 2008;90(11):1159–66.
[28] Bruinsgaard H, Skinhøj P, Pedersen AN, Schroll M, Pedersen B. Ageing, tumour necrosis factor-alpha (TNF-α) and atherosclerosis. Clin Exp Immunol 2000; 121(2):255–60.
[29] Cisizar A, Ungvari Z. Synergistic effects of vascular IL-17 and TNFα may promote coronary artery disease. Med Hypotheses 2004;63(4):696–8.
[30] Cisizar A, Labinskyy N, Smith K, Rivera A, Orosz Z, Ungvari Z. Vasoactive anti-
factors of the anti-tumor necrosis factor-alpha treatment in aging. Am J Pathol 2007; 171(1):388–98.
[31] Arenas IA, Xu Y, Davidge ST. Age-associated inflammation in vascular remodeling to fluid shear stress in the female vasculature is improved by TNF-alpha antagonism. Am J Physiol Heart Circ Physiol 2006;290(3(1)):H259–63.
[32] Ungvari Z, Orosz Z, Labinskyy N, Rivera A, Xiangmin Z, Smith K, et al. Increased mitochondrial H2O2 production promotes endothelial NF-κappaB activation in vascular smooth muscle cells in aorta in adults. JACC Cardiovasc Imaging 2008;1(6):739–48.
[33] Zicha J, Behuliak M, Pintérová M, Bencze M, Kuneš A. Harvey et al. / Journal of Molecular and Cellular Cardiology 83 (2015) 112–121
Anselmi CV, Malovini A, Roncarati R, Novelli V, Villa F, Condorelli G, et al. Association of FOXO3A locus with extreme longevity in a southern Italian centenarian study. Rejuvenation Res 2009;12(2):95–101.

Castrillon DH, Miao L, Kollipara R, Horner JW, DePinho RA. Suppression of ovarian follicle activation in mice by the transcription factor Foxo3a. Science 2003;301(5630):215–19.

Dohi Y, Kojima M, Sato K, Lüscher TF. Age-related changes in vascular smooth muscle cells: from physiology to pathology. Adv Exp Med Biol 2007;56(3):490–502.

Francia P, delli Gatti C, Bachschmid M, Martin-Padura I, Savoia C, Migliaccio E, et al. Vascular functional alterations during aging. Biogerontology 2007;8(6):271–80.

Lønning P, Elvik R, Skard M. An updated review of smoking and lung cancer in Norway. Nord J Psychiatry 2000;54(7):497–503.

Kilkenny C1, B K, Langenbruch C, JACOB S, Richter H, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that report measures of effect with uncertainty: explanation and elaboration. PLoS Med 2009;6(7):e1000100.

Lønning P, Kleven A, Kvaloy S. Systematic review of smoking and lung cancer in Norway. Nord J Psychiatry 2000;54(7):497–503.
de Cavanagh EMV, Piotrkowski B, Basso N, Stella I, Inserra F, Ferder L, et al. Enalapril attenuates hypertrophy in aging female Dahl salt-sensitive rats. Hypertension 2004;44(4):405–9.

Savioa C, Burger D, Nishigaki N, Montezano A, Toury RM. Angiotensin II and the vascular phenotype in hypertension. Expert Rev Mol Med 2011;13:e11.

Cheugh J, Lokhandwala MF, Aughr M. Altered functioning of both renal dopamin D1 and angiotensin II type 1 receptors causes hypertension in old rats. Hypertension 2012 May;59(5):1029–36.

Osako MK, Nakagami H, Shimamura M, Konyama H, Nakagami F, Shimizu H, et al. Cross-talk of receptor activator of nuclear factor-kappaB ligand signaling with renin-angiotensin system in vascular calcification. Arterioscler Thromb Vasc Biol 2013;33(6):1287–96.

Gonzalez GE, Rhaleb NE, D'Ambrosio MA, Nakagawa P, Liu Y, Leung P, et al. Deletion of interleukin-6 prevents cardiac inflammation, fibrosis and dysfunction without affecting blood pressure in angiotensin II-high salt-sustained hypertension. J Hypertens 2015;33(1):143–52.

Panza JA, Casino PR, Kilcoyne CM, Quyyumi AA. Role of endothelium-derived nitric oxide in hypertension. Cardiovasc Res 2014;102(3):460–8.

Hannemann A, Wallaschofski H, Lüdemann J, Völzke H, Markus MR, Rettig R, et al. Plasma aldosterone levels and aldosterone-to-renin ratios are associated with endotheial dysfunction in young to middle-aged subjects. Atherosclerosis 2011;219(2):875–9.

Paar M, Pavenstädt H, Kusche-Vihrog K, Drüppel V, Oberleithner H, Kliche K. Endothelial cellular senescence is inhibited by nitric oxide: implications in atherosclerosis associated with menopause and diabetes. Proc Natl Acad Sci U S A 2006;103(45):17018–23.

Chen Y, Zhao K, Yu Y, Mani S, Cao Q, Puikula S, et al. Hydrogen sulfide protects against cellular senescence via S-sulfhydration of Keap1 and activation of Nrf2. Antioxid Redox Signal 2013;18(15):1906–11.

Franklin SS, Gustin IV W, Wong ND, Larson MG, Weber MA, Kannel WB, et al. Moddy patterns of age-related changes in blood pressure. The Framingham Heart Study. Circulation 1997;96(1):308–15.

Miles EA, Rees D, Banerjee T, Cazzola R, Lewis S, Wood R, et al. Age-related increases in circulating inflammatory markers in men are independent of BMI, blood pressure and blood lipid concentrations. Atherosclerosis 2008;196(1):298–305.

Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38(4):938–42.

Achirfat MR, Aboujada V, Sainte-Rose C, Girard M, Taillefer G, Girard C, et al. Hydrogen sulfide is an endogenous modulator of leukocyte-mediated inflammation. FASEB J 2006;20(12):2118–20.

Linwin M, Feher J, Niemirsa A, Michalkiewicz J. Primary hypertension is a disease of premature vascular aging associated with neuro-immuno-metabolic abnormalities. Pediatr Nephrol Feb. 28 2015. http://dx.doi.org/10.1007/s00467-015-3065-y [Epub ahead of print].